Insider · CIK 0001266567
Brian G Atwood
Files at CERO (CERO THERAPEUTICS HOLDINGS, INC.). First filing -, latest -.
In brief
Brian G Atwood files SEC Form 4 as director and CEO at CERO (CERO THERAPEUTICS HOLDINGS, INC.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Brian G Atwood has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 7, 2026 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,612,099 | $0.00 | $0 | 1,612,099 | Jan 9, 2026 |
| May 30, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +122,549 | $0.00 | $0 | 122,549 | Jun 2, 2025 |
| Mar 31, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | MOption exercise Common Stockindirect: See Footnote | +294,460 | $0.00 | $29 | 490,534 | Apr 4, 2025 |
| Mar 31, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | MOption exercise Pre-Funded Warrantderivative | +294,460 | $0.00 | $29 | 11,660 | Apr 4, 2025 |
| Mar 4, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +14,936 | $0.00 | $0 | 14,936 | Mar 6, 2025 |
| Feb 24, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +254,000 | $0.00 | $0 | 508,000 | Feb 26, 2025 |
| Feb 7, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Pre-Funded Warrantderivative | +306,120 | $0.00 | $31 | 306,120 | Feb 7, 2025 |
| Feb 7, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Pre-Funded Warrantderivativeindirect: By GVN, LLC | +204,080 | $0.00 | $20 | 204,080 | Feb 7, 2025 |
| Feb 7, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Warrant to Purchase Shares of Common Stockderivative | +306,120 | $1.96 | $600k | 306,120 | Feb 7, 2025 |
| Feb 7, 2025 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Warrant to Purchase Shares of Common Stockderivativeindirect: By GVN, LLC | +204,080 | $1.96 | $400k | 204,080 | Feb 7, 2025 |
| Dec 2, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +254,000 | $0.00 | $0 | 254,000 | Dec 4, 2024 |
| Mar 25, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Stock Option (Right to Buy)derivative | +1,317,956 | $0.00 | $0 | 1,317,956 | Mar 27, 2024 |
| Feb 14, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | JOther Common Stock | +125,000 | - | - | 125,000 | Feb 16, 2024 |
| Feb 14, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | JOther Common Stockindirect: Atwood-Edminster Trust dtd 4-2-2000 | +100,527 | - | - | 100,527 | Feb 16, 2024 |
| Feb 14, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | JOther Common Stockindirect: Atwood-Edminster Trust dtd 4-2-2000 | +148,208 | - | - | 248,735 | Feb 16, 2024 |
| Feb 14, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | AGrant or award Series A Convertible Preferred Stockderivativeindirect: Atwood-Edminster Trust dtd 4-2-2000 | +1,002 | $1,000.00 | $1.0M | 1,002 | Feb 16, 2024 |
Questions about Brian G Atwood
Answered from the filings on this page, as of the latest one.
Is Brian G Atwood buying or selling?
Brian G Atwood has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Brian G Atwood's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian G Atwood has 0.
Where does Brian G Atwood file Form 4?
Brian G Atwood has filed Form 4 at CERO (CERO THERAPEUTICS HOLDINGS, INC.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.